1 / 9

Role of Pharmacovigilance Literature Screening in Drug Safety

Growing incidence of chronic ailments and the ease with which drugs are now available is augmenting the rate at which drugs are bought and consumed. According to medical literature, these are factors that have led to an immense growth in the market for pharmacovigilance. Easy obtainability of targeted as well as personalized drugs has given rise to worries associated with the negative impact of drugs. Government directives which are stringent with regards to drug safety, have forced pharmaceutical organizations to embrace effective surveillance strategies to monitor negative reactions to drugs, thereby, furthering the need for extended services within pharmacovigilance.<br><br>Learn More: http://bit.ly/3830WuR<br><br>Need Help: <br>Uk: 44- 7424810299<br>Email: sales@pepgra.com<br>Whatsapp: 91 9884350006<br>

pepgra
Download Presentation

Role of Pharmacovigilance Literature Screening in Drug Safety

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. CHALLENGES AND SOLUTIONS TO PHARMACOVIGILANCE LITERATURESCREENING TAGS: Pharmacovigilance Definition | Good Pharmacovigilance Practice | Pharmacovigilance certification|PharmacovigilanceConsultant|Drugsafetyandpharmacovigilance|Signal detection in pharmacovigilance| Clinical Research monitoring | Global Regulatory Writing | Patient Recruitment | Data Management | Post MarketSurveillance Copyright © 2019 pepgra. All rightsreserved

  2. Background Adverse drug reactions assume much significance in terms of risk associated with safety of patients and could make a major impact on costs related to healthsystems. Owing to its significant implications for public health and safety of patients, regulatory authorities around the worldhaveenforcedandputintopracticenovellegislationsrelatedtopharmacovigilanceinrecenttimes. Activities related to pharmacovigilance largely hinges on undertakings for signal detection, which is executed on data assimilated from impulsive reportingsystems. Health professionals tend to under-report any adverse drug reactions, the focus of new legislations are largely on pertinence of other safety informationsources. Scientific and medical literaturecould prove to be a substantial source for valid information in order to monitor the risk-benefit balance and safety profile of medicinal products. Copyright © 2019 pepgra. All rightsreserved Clinical Research monitoring | Global Regulatory Writing | Patient Recruitment | Data Management | Post MarketSurveillance

  3. PharmocovigilanceRegulations Regulations related to Pharmacovigilance have concentrated largely on Medical Literature Monitoring(MLM), which is a complex procedure, the scope of which continues to deepen andwiden. Current regulations offer in-depth guidance on medical literature searches and review in order to facilitate reportingof individual Case Safety Reports (ICSRs) those that have not been directly reported to the sponsor, while helping signal detection. Copyright © 2019 pepgra. All rightsreserved Clinical Research monitoring | Global Regulatory Writing | Patient Recruitment | Data Management | Post MarketSurveillance

  4. Literature screening is a key element of pharmacovigilance. Medical and scientific literature emerges as a vital information source on cases of suspected adverse drugreactions. Pharmacovigilance and Literature Screening: TheLink Main objective of the screening is to recognize ICSR and / or any substantially new information from studies pertaining to safety and efficacy. Such studies might not be covered through current product labeling and / or any deviation from the existing safety information pertaining to the productlabel. Copyright © 2019 pepgra. All rightsreserved Clinical Research monitoring | Global Regulatory Writing | Patient Recruitment | Data Management | Post MarketSurveillance

  5. Challenges The continuous growth in the number of sources for data or information, combined with the regulatory requirements could render the procedure to be a rather formidableproposition. Teams functioning in the domain of pharmacovigilance are under duress to come up with strategies that are not only flexible but extensive too as. Pharmaceutical organizations are confronted by several challenges in terms of scientific literaturescreening. Contd. Clinical Research monitoring | Global Regulatory Writing | Patient Recruitment | Data Management | Post Market Surveillance Copyright © 2019 pepgra. All rightsreserved

  6. Pharmaceutical organizations are faced with the issue of amalgamating the continuously growing data on safety from literature, within their efforts towards pharmacovigilance. This is done with the objective of being compliant with regulations that are applicable. Literature screening for product citations emerges to be a humongoustask. This requires significant time (in excess) to be invested, cost and effort of sifting through large volumes of cross-disciplinary and heterogeneous reports. Copyright © 2019 pepgra. All rightsreserved Clinical Research monitoring | Global Regulatory Writing | Patient Recruitment | Data Management | Post MarketSurveillance

  7. The European Medicine Agency’s (EMA) latest initiative (September, 2015) is focused on lowering the number of duplicates in terms of monitoring medical literature and efforts at review by the Marketing Authorization Holders (MAHs). Solution This initiative has the potential to enhance monitoring of drugs for safety by improving the consistency and quality ofinformation(EudraVigilance). Monitoring medical literature and entering pertinent data within EudraVigilance would be executed by the EMA in order to improve adverse drug reaction reportingefficiency. ICSRs found within the literature would be rendered available to MAHs, enabling them to incorporate it within their safety databases while meeting their obligations in terms of reporting. Clinical Research monitoring | Global Regulatory Writing | Patient Recruitment | Data Management | Post MarketSurveillance

  8. Conclusion There is a gnawing need for the industry to adopt novel, extensive, cost-effective and efficient solutions for medical literature screening and review with a view to match the continuously evolving marketing, regulatory and strategic requirements. In order to ensure regulatorycompliance, Pharmaceutical organizations should adopt enhanced tools and procedures that allow triage, monitor and review pertinent articles from every literature sourceavailable. This has to be rather rapid as well as accurate and at the same time should also have the capability to interrogate and incorporate new streams ofdata. Suchsolutionsneedtofacilitateincorporationofsafetydatafromdiversesourceswithinasingleunified repository throughout the whole lifecycle of theproduct. Clinical Research monitoring | Global Regulatory Writing | Patient Recruitment | Data Management | Post MarketSurveillance

  9. GETINTOUCH WITH US ContactUs EMAIL ADDRESS sales@pepgra.com Freelancer Consultant PHONE NUMBER +919884350006 +44- 7424810299 Guest BlogEditor EMAIL ADDRESS hr@workfoster.com Clinical Research monitoring | Global Regulatory Writing | Patient Recruitment | Data Management | Post MarketSurveillance Copyright © 2019 pepgra. All rightsreserved

More Related